CLEARSIGNAL

CLEARSIGNAL

Turning Clinical Promise Into Institutional Yes

Turning Clinical Promise Into Institutional Yes

THE CLEARSIGNAL CLARITY & ADOPTION AUDIT™

THE CLEARSIGNAL CLARITY & ADOPTION AUDIT™

Stop Guessing

Stop Guessing

Stop Guessing

Stop Guessing

Why Adoption Stalls.

Why Adoption Stalls.

Why Adoption Stalls.

Why Adoption Stalls.

Start Knowing.

Start Knowing.

Start Knowing.

Start Knowing.

Before you invest in more messaging, another round of sales training, or a redesigned slide deck, you need to know one thing: where adoption is actually breaking down. The Audit finds the specific boulders stalling your product — and tells you exactly what to build first.

Before you invest in more messaging, another round of sales training, or a redesigned slide deck, you need to know one thing: where adoption is actually breaking down. The Audit finds the specific boulders stalling your product — and tells you exactly what to build first.

"The deal doesn't die at clinical review. It dies when your champion can't defend it in the room you'll never be in."

"The deal doesn't die at clinical review. It dies when your champion can't defend it in the room you'll never be in."

Find the Financial Boulders — identify exactly where the CFO's case is incomplete and what it will take to reframe your product from a cost to a protection

Find the Financial Boulders — identify exactly where the CFO's case is incomplete and what it will take to reframe your product from a cost to a protection

Surface the Quiet No — uncover the operational questions from nursing, supply chain, and pharmacy that are traveling upward before your champion ever presents

Surface the Quiet No — uncover the operational questions from nursing, supply chain, and pharmacy that are traveling upward before your champion ever presents

Name the Ghost Stakeholders — identify the billing coders, EHR teams, and compliance officers who never vote but can quietly kill a deal before it reaches the committee

Name the Ghost Stakeholders — identify the billing coders, EHR teams, and compliance officers who never vote but can quietly kill a deal before it reaches the committee

Get the Survival Prescription — a precise list of what to build, what to stop building, and what your champion needs in their hands before the next committee meeting

Get the Survival Prescription — a precise list of what to build, what to stop building, and what your champion needs in their hands before the next committee meeting

Walk away with clarity — not a theory, not a framework, but a specific map of where your adoption is breaking down and exactly what to fix first

Walk away with clarity — not a theory, not a framework, but a specific map of where your adoption is breaking down and exactly what to fix first

WHAT YOU RECEIVE

Prioritized Friction Map

Prioritized Friction Map

Hidden No-Go Report

Hidden No-Go Report

Field Reality Check

Field Reality Check

Survival Prescription

Survival Prescription

The Debrief

The Debrief

The Audit by the Numbers

The Audit by the Numbers

The Audit by the Numbers

$5,000

$5,000

$5,000

$5,000

Investment. ClearSignal only accepts Audit engagements where institutional friction is clearly identified during the discovery conversation. If the fit isn't right, I'll tell you before we move forward.

Investment. ClearSignal only accepts Audit engagements where institutional friction is clearly identified during the discovery conversation. If the fit isn't right, I'll tell you before we move forward.

Investment. ClearSignal only accepts Audit engagements where institutional friction is clearly identified during the discovery conversation. If the fit isn't right, I'll tell you before we move forward.

17

17

17

17

Average gap from clinical evidence

to standard practice

Average gap from

clinical evidence

to standard practice

Average gap from clinical evidence

to standard practice

5

5

5

5

Deliverables — including a live

debrief call

Deliverables — including

a live debrief call

Deliverables — including a live

debrief call

1

1

1

1

Diagnostic built specifically for wound care biologics and regenerative bioscience

Diagnostic built specifically for wound care biologics and regenerative bioscience

Diagnostic built specifically for wound care biologics and regenerative bioscience

THE THREE BOULDERS

Where Adoption Breaks Down — and What the Audit Finds

Most products don't stall because the science is weak. They stall at one of three predictable friction points. The Audit finds exactly which one — and what it will take to clear it.

01

Financial Risk: The CFO's Wall

The committee sees a $3,000 line item. They don't see the $45,000 readmission it prevents. Nobody has translated the clinical value into the institution's financial language — and until that translation exists, the safest move in the room is always to pause.

That's not a pricing problem. It's a framing problem. And it's fixable.

02

Operational Anxiety: The Floor's Resistance

Long before the committee votes, nursing leadership, supply chain, and pharmacy are already asking questions nobody has answered — where does it live, how long does prep take, who handles the charting. If those answers aren't in the room, the floor becomes a quiet no that travels upward fast.

The Audit surfaces those unanswered questions before they kill the next meeting.

03

Clinical Inertia: The Status Quo Is Free

The current standard of care is already budgeted, already trained for, already defended. Asking a committee to replace it means asking them to absorb new risk — clinical, financial, operational, reputational — all at once. Without a clear case for why change is safer than staying put, "not right now" is always the easiest answer in the room.

Clinical Inertia isn't stubbornness. It's institutional self-preservation. The Audit shows you how to address it.

THE THREE BOULDERS

Where Adoption Breaks Down — and What the Audit Finds

Most products don't stall because the science is weak. They stall at one of three predictable friction points. The Audit finds exactly which one — and what it will take to clear it.

01

Financial Risk: The CFO's Wall

The committee sees a $3,000 line item. They don't see the $45,000 readmission it prevents. Nobody has translated the clinical value into the institution's financial language — and until that translation exists, the safest move in the room is always to pause.

That's not a pricing problem. It's a framing problem. And it's fixable.

02

Operational Anxiety: The Floor's Resistance

Long before the committee votes, nursing leadership, supply chain, and pharmacy are already asking questions nobody has answered — where does it live, how long does prep take, who handles the charting. If those answers aren't in the room, the floor becomes a quiet no that travels upward fast.

The Audit surfaces those unanswered questions before they kill the next meeting.

03

Clinical Inertia: The Status Quo Is Free

The current standard of care is already budgeted, already trained for, already defended. Asking a committee to replace it means asking them to absorb new risk — clinical, financial, operational, reputational — all at once. Without a clear case for why change is safer than staying put, "not right now" is always the easiest answer in the room.

Clinical Inertia isn't stubbornness. It's institutional self-preservation. The Audit shows you how to address it.

THE THREE BOULDERS

Where Adoption Breaks Down — and What the Audit Finds

Most products don't stall because the science is weak. They stall at one of three predictable friction points. The Audit finds exactly which one — and what it will take to clear it.

01

Financial Risk: The CFO's Wall

The committee sees a $3,000 line item. They don't see the $45,000 readmission it prevents. Nobody has translated the clinical value into the institution's financial language — and until that translation exists, the safest move in the room is always to pause.

That's not a pricing problem. It's a framing problem. And it's fixable.

02

Operational Anxiety: The Floor's Resistance

Long before the committee votes, nursing leadership, supply chain, and pharmacy are already asking questions nobody has answered — where does it live, how long does prep take, who handles the charting. If those answers aren't in the room, the floor becomes a quiet no that travels upward fast.

The Audit surfaces those unanswered questions before they kill the next meeting.

03

Clinical Inertia: The Status Quo Is Free

The current standard of care is already budgeted, already trained for, already defended. Asking a committee to replace it means asking them to absorb new risk — clinical, financial, operational, reputational — all at once. Without a clear case for why change is safer than staying put, "not right now" is always the easiest answer in the room.

Clinical Inertia isn't stubbornness. It's institutional self-preservation. The Audit shows you how to address it.